Boehringer Ingelheim is taking over Amgen’s Fremont, CA, development and manufacturing facility in a deal that gives it all Amgen’s rights and substantially all its assets. The transaction has been approved by the board of directors of each company and is expected to close in March of this year.
Boehringer Ingelheim has been a contract manufacturer for Amgen for more than 10 years and will continue to support Amgen’s manufacturing needs. The Amgen Fremont site currently employs approximately 360 employees and has 100,000 square feet of manufacturing space including a pilot plant and process-development labs. Amgen obtained the facility through its 2006 acquisition of Abgenix.
“The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business including new biological entity process-development and manufacturing efforts,” notes Wolfram Carius, head of Boehringer Ingelheim’s board of managing directors.
Boehringer Ingelheim’s services span mammalian cell line and microbial strain development to final drug production and global market supply. It has experience in multiple molecule classes such as mAbs, recombinant proteins, interferons, enzymes, fusion molecules, novel scaffold proteins, and plasmid DNA.
Boehringer Ingelheim is headquartered in Ingelheim, Germany, and operates globally with 142 affiliates in 50 countries and more than 41,500 employees. In 2009, Boehringer Ingelheim posted net sales of €12.7 billion.